In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals In Depth: December 2019

Executive Summary

Gene therapy dominated the top December deals, with a $2.9bn alliance between Roche and Saretpta for DMD treatment SRP9001, and Astellas's $3bn acquisition of Audentes Therapeutics. Follow-on public offerings made up close to or more than half of both biopharma and device financing.

You may also be interested in...



The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

Seven Key Success Factors In Market Opportunity Assessments

In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.

EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021

Coming year could feature first-time approvals in the EU for at least five gene therapies.

Topics

Latest News
UsernamePublicRestriction

Register

IV124434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel